ADC Therapeutics' Cash And Cash Equivalents Were $300.1M As Of June 30, Extending The Expected Cash Runway Into Mid-2026
Portfolio Pulse from Benzinga Newsdesk
ADC Therapeutics reported having $300.1 million in cash and cash equivalents as of June 30, which extends their expected cash runway into mid-2026.
August 06, 2024 | 11:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ADC Therapeutics reported $300.1 million in cash and cash equivalents as of June 30, extending their cash runway into mid-2026.
The significant cash reserves and extended runway provide financial stability and reduce the risk of near-term liquidity issues, which is positive for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100